Contribute Try STAT+ Today

As Purdue Pharma attempts to win a controversial reorganization plan in bankruptcy court, the drug maker is also seeking approval for $34.7 million in employee bonuses, including $2.1 million for the chief executive officer.

The request, which was filed in a court motion earlier this week, raises the possibility of yet another round of outrage over bonuses the company wants to pay its employees. Last year, a handful of Senate Democrats slammed the drug maker for seeking to reward its executives and argued the move was offensive to thousands of families harmed by the opioid crisis. Even so, the bonuses were approved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment